Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isoniazid for TB Prevention in HIV-Exposed Infants
NCT00080119Phase 3Terminated
- Sponsor
- IMPAACT Network
- Start
- Feb 2004
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of isoniazid in Tuberculosis (TB) (4 arms), sponsored by IMPAACT Network. Primary endpoints: Time to Development of Tuberculosis (TB) Disease or Death Among HIV-infected Children at 96 weeks and Time From Randomization to Development of TB Infection or Death Among Perinatally Exposed, HIV-uninfected Children at 96 weeks. Started Feb 2004; status: terminated.
02
Drugs
isoniazid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT00080119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00080119.